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Abstract
Background: To systematically investigate the current status and methodology of health technology reassessment
(HTR) in various countries to draw insights for the healthcare system in South Korea.
Methods: A systematic literature search was conducted on the articles published between January 2000 and February
2015 on Medline, EMBASE, the Cochrane Library, CINAHL, and PubMed. The titles and abstracts of retrieved records were
screened and selected by two independent reviewers. Data related to HTR were extracted using a pre-standardised form.
The review was conducted using narrative synthesis to understand and summarise the HTR process and policies.
Results: Forty five studies, conducted in seven countries, including the United Kingdom, Australia, Canada, Spain,
Sweden, Denmark, and the United States of America, fulfilled the inclusion criteria. Informed by the literature review,
and complemented by informant interviews, we focused on HTR activities in four jurisdictions: the United Kingdom,
Canada, Australia, and Spain. There were similarities in the HTR processes, namely the use of existing health technology
assessment agencies, reassessment candidate technology identification and priority setting, stakeholder involvement,
support for reimbursement coverage, and implementation strategies. Considering the findings of the systematic review
in the context of the domestic healthcare environment in Korea, an appropriate HTR model was developed. This
model included four stages, those of identification, prioritisation, reassessment and decision.
Conclusions: Disinvestment and reinvestment through the HTR was used to increase the efficiency and quality of care
to help patients receive optimal treatment. Based on the lessons learnt from other countries’ experiences, Korea should
make efforts to establish an HTR process that optimises the National Healthcare Insurance system through revision of
the existing Medical Service Act.
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Background
In South Korea, health expenditures have increased
rapidly since the introduction of the national health
insurance in the second half of the 1980s. Between 2000
and 2009, the rate of increase in health spending in
South Korea was more than twice the average across
OECD countries, reaching and average of 9.8% per year
in real terms, compared to that of 4.8% in OECD coun-
tries [1]. Although there has been an improvement in
the assessment of new health technologies in Korea
since the introduction of a formal assessment procedure
in 2007, an efficient mechanism to promote the reassess-
ment and management of obsolete health technologies is
yet to be established. In particular, there have been rising
concerns about new technologies introduced to the mar-
ket after being evaluated in new health technology assess-
ment (HTA) programs with regards to patients’ safety and
the efficiency of the National Health Insurance system.
Leggett et al. [2] reported that there were some uncertain-
ties regarding the safety and effectiveness of new health
technologies and the obsolescence of existing technologies
because of their lifecycle. Therefore, reassessment of their
safety and effectiveness has been required since the intro-
duction of the new technology under health insurance
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coverage. In the 2012 Health Policy Forum of Health
Technology Assessment International [3], health technol-
ogy reassessment (HTR) was proposed as an integral part
of HTA agencies in order to enhance the optimal use of
health technologies and to ensure value for money.
In December 2008, the National Evidence-based health-
care Collaborating Agency (NECA) was established to take
charge of HTA and economic evaluation research in South
Korea. Subsequently, in 2010, the Center for New Health
Technology Assessment was integrated into the NECA [4].
Recently, several countries, such as the United Kingdom,
Australia, Canada, and Spain, have demonstrated growing
interest in HTR development and implementation. How-
ever, there was no systematic literature review of HTR to
determine its current status and provide insight for other
countries planning to introduce a similar system. There-
fore, the aim of this study was to systematically review the
HTR-related literature to examine (1) the organisation/
governance of HTR; (2) the process used for identifying
candidate technology for reassessment and candidate tech-
nology prioritisation; (3) the stakeholder engagement,
decision-making processes, and implementation strategies;
and (4) the general HTR landscape to obtain insights into
developing HTR in South Korea.
Methods
Literature search and inclusion criteria
We searched the literature published from January 2000
to February 2015 using electronic databases including
Medline, EMBASE, the Cochrane Library, CINAHL, and
PubMed. In order to develop a comprehensive search
strategy, we performed the pilot search using MeSH terms
or keywords mentioned in key references related to HTR.
We conducted the search using a comprehensive combin-
ation of keywords, such as “disinvestment”, “obsoles-
cence”, “ineffective”, “reassessment”, “reallocation”,
“program budgeting”, “abandoned”, “optimal practice or
use”, “health investment or reinvestment”, and “value for
money” (Table 1). Thirty-two of the 53 Health Technology
Assessment International (HTAi) and International
Network of Agencies for Health Technology Assessment
(INAHTA) members had accessible English websites,
which were searched to identify related unpublished
reports. Additionally, other relevant studies were searched
by manually screening the reference lists of the studies
included in the search.
The following inclusion criteria were employed: studies
reporting the current status of HTR activities or HTR
process including the HTR agencies, candidate technology
identification and priority setting, HTR methodologies,
stakeholder involvement, and political support for imple-
mentation. Only studies published in English or Spanish
were included.
Study selection
Two authors independently screened the titles and ab-
stracts according to pre-defined inclusion and exclusion
criteria. The full-texts of the potentially relevant studies
were retrieved to assess eligibility for inclusion, and any
disagreements were resolved through a discussion with
the third author.
Data extraction and analysis
Two trained reviewers from the research team ex-
tracted the data from the articles. Subsequently, the
other authors verified the extracted data. A structured
data extraction form was developed to ensure uniform-
ity and the extraction of all relevant information. This
included the year of introduction of HTR, presence of
legislation, agency in charge of reassessment, financial
support, method of identifying reassessment candidate
technology, reassessment priority setting, reassessment
methodology, recommendations and decisions on
reassessment results, disinvestment decision-making
bodies and committee composition, implementation
strategies, and stakeholder engagement. Information
about HTR in four countries was summarised using
descriptive methods. The results of the literature review
were supplemented by data collected through inter-
views with informants involved in the HTR processes.
Additionally, informants from the United Kingdom and
Spain were visited through formal contacts in the NICE
(National Institute for Health and Care Excellence) and
Osteba (Basque Office for Health Technology Assess-
ment) organisations. Informants were asked about the
overall HTR policy, executive difficulties, and examples




“The complete or partial removal of a health technology based on evidence that it is clinically ineffective and/or financially
inefficient” [2].
“The process of withdrawing (partially or completely) health resources from those existing healthcare practices, procedures,




“A structured, evidence-based assessment of the clinical, social, ethical & economic effects of a technology currently used in
the health care system, to inform optimal use of that technology in comparison to its alternatives” [2]
Obsolescence “The end point of all technology, which can progress through a lifecycle that encompasses ideas, innovation, invention,
investigation, adoption, acceptance, reduced use, and obsolescence” [21]
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information from the literature review. We performed a
narrative synthesis rather than a quantitative one using
meta-analysis to summarise and investigate the process,




The electronic database and grey literature search, in-
cluding the HTAi and INAHTA websites, yielded
20,395 records, of which the full text of 8045 articles
were read after excluding duplicates. Sixty full text arti-
cles were retrieved and scrutinised, independently by
two reviewers, as potential studies after screening the
titles and abstracts. Among them, 23 articles were ex-
cluded due to the following reasons: not related to
HTR programs (n = 18), and not an original article
(such as letter and comments) (n = 5). Manual screen-
ing of the reference lists of included studies yielded
eight additional articles. Thus, a total of 45 studies met
the inclusion criteria (Fig. 1).
HTR governance and procedures
Governance and organisation
The governance and performance of HTR can be af-
fected by whether an HTR system has legal support to
operate within the system. In the United Kingdom, in
addition to the NICE, MaCSWise (Making Choices,
Spending Wisely) was established in April 2011 as a
short-term return-on-investment promotion group to
focus on reassessment and reinvestment within the
Scottish Health Technologies Group and National
Health System [5]. In Canada, there have been initia-
tives aimed at prioritising, developing assessment
methods for, and implementing approaches [6]. In par-
ticular, HTR has been actively implemented in Ontario,
Alberta, Vancouver Island, and Calgary since the 1990s
[2]. Australia has been moving forward to establish
disinvestment at the local level by developing the
Australasian Registry of Obsolete Health Technologies
Evaluated for Disinvestment [7–9]. Spain has regulatory
support on a national level, called the Royal Decree
1030 [10], while Osteba in the Basque area and the
Galician Agency for Health Technology Assessment
(Avalia-t) in the Galicia area play leading roles in HTR
at the regional level [11, 12] (Table 2).
Existing HTA agencies are responsible for HTR im-
plementation, such as the Danish Centre for Evaluation
and Health Technology Assessment in Denmark [13],
the Swedish Council on Health Technology Assessment
in Sweden [14], and the Canadian Agency for Drugs
and Technologies in Health in Canada [6]. In the
United States of America, a 2008 report from the US
Congressional Budget Office emphasised the import-
ance of comparative effectiveness research as a basis for
ensuring the use of emerging and expensive health tech-
nologies with superior clinical benefits compared to alter-
native and inexpensive health services [15]. As a result,
the Patient-Centered Outcomes Research Institute has
been established as an integrated public–private agency to
Fig. 1 Study selection flow diagram
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oversee the program, although it excludes consideration
of cost-effectiveness implications. Information obtained
from the agency’s evaluation is expected to change tech-
nology use by promoting better decision making among
consumers, the commissioner, policymakers and clinicians
[13]. Establishing HTR organisations and the presence of
legal support have a direct effect on policy decision-
making, such as decisions on health insurance reimburse-
ment, and influence the implementation of decisions such
as discontinuing the use of obsolete health technologies in
clinical practice.
Reassessment methodology
The HTR methodology is not very different from that of
the HTA [3]. However, to overcome stakeholder resistance,
HTR requires convincing evidence of at least no risk, or of
a benefit, in removing the technology. Unlike evidence for
new technology, providing clear evidence for the benefit or
harm of established technology is more difficult. Therefore,
assessments of technologies in regular use frequently
depend on the analysis of routine health system data [16].
The United Kingdom’s NICE developed three strategies to
support the HTR process, namely technology appraisal, rec-
ommendation reminders, and commissioning guidelines. In
order to establish a basis for any decision to reduce or elim-
inate funding for specific technologies, a rigorous approach
to evidence is required, with reliable data from high quality
studies [7].
Identifying candidate technologies for reassessment
Most countries have similar criteria for identifying HTR
candidates, which are as follows: (1) new evidence, that
is, when new evidence of safety, effectiveness and cost-
effectiveness is accumulated in subsequent trials, meta-
analysis, post-market surveillance, audits, and registry
data, geographic and providers’ variations in care are
observed, temporal variations in volume are observed (e.g.
2, 3, or 5 years), there is evidence of public interest or dis-
putes (which involves the voicing of negative (or ineffect-
ive) responses to treatment by patients or consumer
advocacy and community groups), and there is conflict
with guidelines or discrepancies between practices and
clinical practice guidelines, the Cochrane review recom-
mendations, etc. [17]. In the United Kingdom, the NICE
health technology appraisal criteria are applied to dis-
investment in a way similar to investment [18]. However,
NICE might consider additional criteria. It might be rele-
vant to establish a starting point when there is high geo-
graphical variation in healthcare service utilisation [19].
To identify treatments with little or no evidence of benefit,
NICE began to use the Cochrane Library [18] and clinical
practice guidelines to identify candidates for disinvestment
[20] (Table 3).
In the United States, the Institute of Medicine devel-
oped a topic list of priorities for technology reassessment
and for the development of candidate technologies for re-
assessment. Similar to other countries, its identification of
candidate technologies for reassessment involves searches
of unnecessary, ineffective or harmful interventions, and
the systematic investigation of variations in clinical prac-
tices. The Institute of Medicine’s candidates for potential
disinvestment are existing health technologies that show a
decreased frequency of use because of problems regarding
their safety and effectiveness [13].
Prioritisation of candidate technologies
Several countries shared common prioritisation criteria
for disinvestment, including the following: the cost of the
technology has a major impact on the total budget; the
benefit of technology is small [7]; the cost per procedure
and by volume is high; low degree of disease or burden,
especially in vulnerable populations [17]; experience-
Table 2 Organisation/governance and methods of health technology reassessment in the main countries reviewed
United Kingdom Canada Australia Spain
Legal support No No No Yes
Level of performance National Regional National and regional Regional

















Commissioners’ guides “Do not do”
database
Recommendation Recommendation Report
CADTH Canadian Agency for Drugs and Technologies in Health, MSAC Medical Services Advisory Committee, PBAC Pharmaceutical Benefits Advisory Committee,
HealthPACT Health Policy Advisory Committee for Technology, Osteba Basque Office for Health Technology Assessment, Avalia-t Galician Health Technology
Assessment Agency, NICE National Institute for Health and Care Excellence
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Table 3 Criteria for the identification of health technology reassessment in the main countries reviewed
United Kingdom Canada Australia Spain
Identification Selection criteria for medical
technologies evaluation in NICE
- Claimed additional benefit to patients





- New evidence (safety, effectiveness)
- Geographic variations in care
- Provider variations in care (clinical
heterogeneity)
- Temporal variations in volume (a trend in
item volume between time points)
- Technology development
- Public interest or controversy
- Consultation
- Nomination
- Assess new intervention, displace old
- Leakage
- Legacy items
- Conflict with guidelines
- Precedent
- New evidence (safety, effectiveness)
- Geographic variations in care
- Provider variations in care (clinical
heterogeneity)
- Temporal variations in volume (a trend in
item volume between time points)
- Technology development
- Public interest or controversy
- Consultation
- Nomination
- Assess new intervention, displace old
- Leakage
- Legacy items
- Conflict with guidelines
Guideline for Not Funding existing health
Technologies in healthcare systems
- Technology to be used in the centre or
place
- Technology status known to the applicant
- Alternative treatment option available
- No absence of care with disinvestment
Detection criteria
- Is currently used (health services portfolio)















based regional requests and decisions; new evidence on
safety, effectiveness and cost-effectiveness; and time-based
criteria (e.g. approval of new health technologies and re-
assessment 5 years after introduction) [21].
In Canada, the “Oversight Committee” model was
proposed to consider the priority-setting process and
strategies to identify potentially obsolescent technolo-
gies [21]. In Spain, the PriTec tool developed by Avalia-
t is used for HTR candidate priority setting, considering
population/end-user factors, a risk-benefit analysis and
costs, as well as organisational factors and other impli-
cations [22] (Table 4).
Stakeholder involvement and decision-making processes for
disinvestment
The decision-making process for reassessment should
be transparent and supported by robust evidence, and
implementation should include appropriate knowledge
transfer to all stakeholders [16]. In order to expedite
the acceptance of individual disinvestment decisions,
the decision-making process should be conducted in
cooperation with patients, who are given sufficient in-
formation regarding the reasons for the decision. The
health professionals who use the technology should
also be informed of the reasons underpinning the de-
cision and be involved in the process of identifying
and evaluating whether a technology is suitable for
disinvestment [23].
In the United Kingdom, the body for decision making
on disinvestment is the Technology Appraisal Committee.
Committee members are drawn from the National Health
Service, patient and caregiver organisations, academia,
and pharmaceutical and medical device industries. Com-
mentator organisations include the manufacturers of
comparator technologies, National Health Service Quality
Improvement Scotland, the relevant National Collaborat-
ing Centre (a group commissioned by NICE to develop
clinical guidelines in areas such as cancer and mental
health), and research groups working in the area [24]. In
Vancouver, Canada, a standard approach to Programme
Budgeting and Marginal Analysis (PBMA) was taken with
a priority-setting working committee that comprised of all
directors and clinical leaders from Vancouver commu-
nities, as well as a broader advisory panel that includes
a mix of personnel and senior executive members from
Vancouver communities. The characteristics of the
decision-making process include the use of a standard
business case template and proposal rating tool, an as-
sessment standard with clearly defined weighted values
related to the health authority’s strategic priorities, and a
public communication plan. Through several delibera-
tions, the research teams provide the modified and refined
standard to the operating committee [25]. Canada’s policy
decision-making process included removal from funding
schedules, partial reimbursement, and risk-sharing with
the health service provider reimbursing the agreed cost to
the insurer. If the outcomes are below expectations, reim-
bursement is given only for guideline adherence, and there
are sunset clauses in financial support regulations, which
stipulate that reimbursement is provided on the condition
that proper periods are set and evidence generated [6]. In
Australia, deliberative democratic methods were adopted
to develop evidence-informed stakeholder engagements
that include clinicians, consumers and representative
community members in the process. The community
consultations were held over 2 days to allow for informa-
tion sharing, deliberation and an understanding of the
HTR reports [26].
Spain’s disinvestment decision-making process follows
the Guideline for Not Funding existing health Technolo-
gies in health care systems (GuNFT), announced in May
2010. The decision-making results include eight possibil-
ities: in favour of the proposal; against the proposal;
against the proposal, but modifiable in the future; against
the proposal because of a lack of evidence, but modifiable
in the future; proposal recommended; proposal not rec-
ommended; proposal not recommended, but can be con-
sidered when the capacity of the centre has been revised;
and proposal not recommended, but modifiable when
new evidence is available [12]. Information asymmetry
Table 4 Criteria for prioritisation of health technology reassessment in the main countries reviewed
United Kingdom Canada Australia Spain
Prioritisation - Budget impact
- Existing alternatives
- Improved patient safety
- Not for vulnerable
populations
- Small benefit
- Close risk/benefit ratio




- Sufficient evidence available
- Scope for time-limited funding
with “pay for evidence” or “only
in research” provisions
- Futility




- Sufficient evidence available
- Scope for time-limited funding





- Burden of disease
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between clinically engaged experts and policy or decision
makers may preclude the truly collaborative, informed
and technical discussions required to generate genuine
change. Overcoming these challenges will require innova-
tive approaches to co-producing evidence syntheses,
broad-based stakeholder engagements, and a sustained
commitment from clinicians and policymakers alike [27].
While PBMA is being used to assess the distribution
of resources for health services and technologies within
a fixed budget plan, HTA review is mainly focused on
specific technologies in the fee-for-service healthcare
payment system [28].
HTR implementation
There appear to be several main barriers to HTR imple-
mentation [16]. First, patients and clinicians tend to
think that the decision to remove an existing health
technology poses a greater disadvantage than the deci-
sion to not accept a new health technology with a simi-
lar value. Second, professional or system inertia is a
particular challenge to overcome. Introducing change to
existing technology is difficult since trained clinicians
consider technology integral to their professional prac-
tice and identity. The clinical training and practice para-
digms can be difficult to change, and organisations
could have invested a considerable amount of money in
the existing technology and capital infrastructure. Third,
to overcome stakeholder resistance, convincing evidence
of no harm from withdrawal and no benefit from tech-
nology use is required. Sometimes stronger evidence is
needed for use reduction or withdrawal decisions than
for other aspects of technology use.
In the United Kingdom, a recommendation reminder is
published monthly, summarising new recommendations
for the use of existing health technologies. The “Do Not
Do” list, recommendation reminders and Commissioners’
guides issued by the NICE list all of the health technolo-
gies that the organisation suggests avoiding or not using
[20]. The Canadian Institute of Health Economics utilises
the Ambassador Program for Knowledge Transfer as a
representative program and is trying to disseminate
reassessment results through Consensus Development
Conferences [29]. In Spain, the GuNFT was developed as
a free software package to facilitate quick and easy com-
munication between stakeholders who are participating in
the process of disinvestment. This software sends emails
containing applications for technologies targeted for
disinvestment to assessors and decision makers. The re-
assessment process and results report are provided after
the evaluation process has been completed [12].
Suggestions to facilitate HTR in experienced countries
Decisions on disinvestment and resource allocation re-
quired deliberative process for ensuring transparency and
objectivity. It needs to articulate definition of disinvest-
ment for various stakeholders because disinvestment may
be understood differently depending on their conflict of
interests. To boost decision-making on disinvestment,
training for resource reallocation methods was provided
to those who participate in panel advisory groups. Add-
itionally, contextual and colloquial evidence as well as
clinical evidence need to be obtained and collated to facili-
tate in-depth discussion in decision-making regarding dis-
investment. Moreover, political support, including political
motivation, transparency and governance, might underpin
the introduction and establishment of HTR.
Specific examples on disinvestment from experienced
countries were as follows. An investigation had been con-
ducted on those who were participating in local-level
commissioning meetings in terms of how they understand
disinvestment and how they implement disinvestment
using ethnographic methods. Most informants, including
commissioners, hospital managers and lay members, had
described disinvestment as funding reduction or with-
drawal from the existing healthcare services, whereas
some participants reported disinvestment as the main
motive of cost-saving. These comments indicated that it
was necessary to provide a clear definition of disinvest-
ment. Further, they pointed out that, while the lack of
information, guidance and time capacity were the practical
barriers for disinvestment, difficulties for collaboration be-
tween commissioners and hospital managers/clinicians
due to distrust were ideological barriers. Therefore, it
would be necessary to encourage hospital managers, clini-
cians and lay members, whose disinvestment was to be
potentially affected, to participate in the decision making
regarding disinvestment, including defining clearly what
disinvestment would be, and to develop the strategies for
an explicit disinvestment agenda in consideration of the
barriers investigated [30].
A study on stakeholders who had used PBMA for
resource reallocation of Vancouver Island Health
Authority in Canada reported that two tasks needed
to be achieved before introducing a new priority-setting
process in healthcare organisations. The first task con-
cerned the procedures addressing the needs of strat-
egies to educate and train a panel advisory group since
the senior decision-makers presented a learning curve
as they became familiarised to the PBMA approach in
the early stage of PBMA implementation. The second
task was to establish the basic principles of decision
making on redistribution, evidence-based decision mak-
ing methods and transparent decision making processes
to explain funding decisions [31].
In Australia, a case study on the use of assisted repro-
ductive technologies (ART) for older women asked phy-
sicians who participated in the process of deliberative
stakeholder engagements about the evidence needed to
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assess the eligibility of ART as a disinvestment candi-
date. The physicians had criticised currency, proxim-
ity, selectivity and bias for statistics drawn from the
Australian and New Zealand Assisted Reproduction
Database, a registry of the outcomes of all initiated
cycles of ART. Thus, the participatory policymaking
process of stakeholders claimed the need for various
empirical (what are the ‘real’ outcomes of ART?),
contextual (contextual factors impacting on ART out-
comes), and anecdotal evidences (data related to
patient behaviours) rather than traditional research
evidence to enable sufficient discussion at the time of
decision making for disinvestment [28, 32].
In a study investigating the barriers related to the
establishment of an agency to perform research that
generates evidence on the funding or selective dis-
investment of the Spanish National Health System, a
panel of experts rated political domains as the main
barriers among the lack of political motivation,
tension between a decentralised health system and
evaluation activities, technical difficulties of the HTR
processes or decision-making, and social and profes-
sional reluctance for the withdrawal of healthcare
benefits [33]. Therefore, it was found that there was
room for improvement to incorporate explicit mecha-
nisms for decision-making on disinvestment of health
technologies in the Spanish national health reimburse-
ment system [34].
Discussion
From our review of the literature from various countries,
we suggested actions that may be taken to improve the
Korean HTR system. Firstly, a formulary legal structure
for HTR was needed in order to increase the impact of
HTR system introduction. The HTA program was intro-
duced in Korea in 2007, focusing on the new HTA sys-
tem of Decree 53 in the Medical Service Act. Therefore,
the existing Medical Service Act could be revised by
adding the tasks related to HTR.
The second is related to the criteria for the identification
and prioritisation of HTR; in most countries, the identifi-
cation of candidates for HTR was performed by direct
searching of biomedical studies, HTA reports, clinical
practice guidelines and new health technology databases,
and by contacting clinical experts. The common criteria
were efficiency, effectiveness, cost-effectiveness, safety,
regional requirement or patient preference, existence of
available substitute, and the cost and burden of the
disease. In Korea, seven “identification” criteria, seven
“prioritisation” criteria and weighted values, and four “re-
assessment” criteria to enable the practical execution of
reassessment were selected using the RAND Method. The
“identification” criteria included safety, controversial effi-
cacy, proposal from Department of Health, Korean
Medical Association and patient related associations,
new evidence on effectiveness, significant changes in
the utilisation frequency of technologies, new findings of
cost-effectiveness of technologies, and variation of re-
gional or providers’ provision. The “prioritisation” criteria
included safety, efficacy, volume on evidence, burden of
diseases, potential impact of reassessment, utilisation of
technologies and cost-effectiveness. Finally, the reassess-
ment criteria for HTR included safety, efficacy or effect-
iveness, efficiency or cost-effectiveness, and infrastructure
of the healthcare system.
Thirdly, HTR methods have been largely based on the
HTA methodology. However, HTR has additional re-
quirements such as no harm due to withdrawal of health
technologies, or strong evidence that the use of the tech-
nology has no benefit. Furthermore, HTR needs to in-
clude the systematic assessment of social value, patient
preference and ethics. Therefore, in order to generate
convincing evidence for the disinvestment of existing
technologies, a new national registry for HTR should be
created to investigate the influence of health technolo-
gies on health outcomes, as well as to analyse existing
national health insurance claims data from the Health
Insurance Review & Assessment Service and National
Health Insurance in Korea.
Finally, the Korean HTR system might classify the top-
down programs initiated by governmental authorities.
The binding clinical practice guideline or reimbursement
in coverage may facilitate the uptake of implementation
of HTR, whereas it can raise resistance of physicians and
consumers related to technologies rated as withdrawal
decision [35]. Therefore, it needs to make a decision
underpinned by the varied involvement and active com-
munication of physicians and various stakeholders,
including patients, insurers and health authorities.
Meanwhile, in South Korea, two HTR pilot projects
began on April 1, 2014, which were expected to con-
tinue for 2 years. The aims of the pilot projects were to
assess feasibility of the introduction and implementation
of HTR program, to refine the objectives of the HTR for
reimbursement coverage or (partial/complete) disinvest-
ment, and to set prioritisation criteria according to ob-
jectives of HTR program. Considering the findings of
this systematic review and the domestic healthcare en-
vironment, we developed a four-stage Korean HTR
model, including “identification”, “prioritisation”, “re-
assessment” and “decision.” First, in terms of identifica-
tion, regarding health technology information collected
through a demand survey conducted by a Government
ministry, related agency and specialised society, or
internal monitoring by the NECA, the identification
criteria already determined are applied to identify the
medical technology eligible for reassessment. Second, in
the prioritisation stage, the reassessment of the selected
Seo et al. Health Research Policy and Systems  (2016) 14:82 Page 8 of 10
health technologies is prioritised based on predeter-
mined prioritisation criteria and weighted values. Third,
for the finally selected health technology, methodologies,
such as systematic review and economic feasibility ana-
lysis, are used based on the reassessment criteria to
execute the HTR. Here, the specialised reassessment
committee (provisional name) provides the mediation
plan based on the details discussed. Finally, in the deci-
sion stage, the Health Technology Assessment Commit-
tee (currently, Committee for nHTA) finally decides and
notifies the reassessment result on the relevant health
technology based on the mediation plan advice (Fig. 2).
This reassessment model was implemented on intestine
capsule endoscopy and intra-disc steroid injections. The
research group plan to collate the data and publish a
progress report and evaluation of the HTR projects. This
will demonstrate Korea’s experience with HTR at the
national level.
This review has some limitations. First, despite the fact
that our review included studies from seven different
countries, we excluded articles written in languages
other than English or Spanish. Second, the included
studies were collected by searching electronic databases
and HTAi member agencies rather than by contacting
experts and researchers in each country, with the excep-
tion of Spain and England. Nevertheless, this was a com-
prehensive review of the literature on HTR, reporting
implications and practical information from other coun-
tries to help introduce HTR in Korea.
Conclusion
The current study reviewed HTR system, focusing on the
United Kingdom, Australia, Canada and Spain. There
were similarities in the HTR processes, including
utilisation of existing HTA agencies, identification and pri-
ority setting of candidate technologies for reassessment,
reassessment methods, and the composition of advisory
committees including various stakeholders.
Disinvestment through HTR was one of the strategies
to increase the efficiency and quality of care to help
patients receive optimal treatment. Based on the lessons
from foreign countries’ experiences, South Korea should
make efforts to develop and establish an HTR system to
optimise the National Healthcare Insurance system.
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